Goldman Sachs Group Inc Tg Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,556,427 shares of TGTX stock, worth $87.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,556,427
Previous 2,084,708 22.63%
Holding current value
$87.6 Million
Previous $37.1 Million 61.23%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$17.21 - $25.28 $8.12 Million - $11.9 Million
471,719 Added 22.63%
2,556,427 $59.8 Million
Q2 2024

Aug 13, 2024
BUY
$13.32 - $19.19 $10.6 Million - $15.3 Million
798,280 Added 62.05%
2,084,708 $37.1 Million
Q1 2024

May 15, 2024
SELL
$13.02 - $21.3 $4.73 Million - $7.74 Million
-363,409 Reduced 22.03%
1,286,428 $19.6 Million
Q4 2023

Feb 13, 2024
SELL
$6.68 - $18.81 $274,634 - $773,335
-41,113 Reduced 2.43%
1,649,837 $28.2 Million
Q3 2023

May 14, 2024
BUY
$8.36 - $26.5 $343,704 - $1.09 Million
41,113 Added 2.49%
1,690,950 $14.1 Million
Q3 2023

Nov 14, 2023
BUY
$8.36 - $26.5 $2.25 Million - $7.14 Million
269,580 Added 18.97%
1,690,950 $14.1 Million
Q2 2023

May 14, 2024
BUY
$15.48 - $35.0 $3.9 Million - $8.82 Million
251,868 Added 21.54%
1,421,370 $35.3 Million
Q2 2023

Aug 14, 2023
BUY
$15.48 - $35.0 $3.9 Million - $8.82 Million
251,868 Added 21.54%
1,421,370 $35.3 Million
Q1 2023

May 14, 2024
SELL
$10.23 - $19.34 $471,183 - $890,781
-46,059 Reduced 3.79%
1,169,502 $17.6 Million
Q1 2023

May 11, 2023
SELL
$10.23 - $19.34 $471,183 - $890,781
-46,059 Reduced 3.79%
1,169,502 $17.6 Million
Q4 2022

May 14, 2024
SELL
$5.01 - $11.83 $1.64 Million - $3.86 Million
-326,360 Reduced 21.17%
1,215,561 $14.4 Million
Q4 2022

Feb 13, 2023
SELL
$5.01 - $11.83 $1.64 Million - $3.86 Million
-326,360 Reduced 21.17%
1,215,561 $14.4 Million
Q3 2022

May 14, 2024
BUY
$4.57 - $8.4 $2.68 Million - $4.93 Million
587,242 Added 61.51%
1,541,921 $9.13 Million
Q3 2022

Nov 10, 2022
BUY
$4.57 - $8.4 $2.68 Million - $4.93 Million
587,242 Added 61.51%
1,541,921 $9.13 Million
Q2 2022

May 14, 2024
SELL
$3.74 - $10.66 $2.6 Million - $7.41 Million
-695,158 Reduced 42.13%
954,679 $4.06 Million
Q2 2022

Aug 15, 2022
SELL
$3.74 - $10.66 $1.41 Million - $4.03 Million
-377,723 Reduced 28.35%
954,679 $4.06 Million
Q1 2022

May 16, 2022
BUY
$7.81 - $20.45 $1.7 Million - $4.44 Million
217,336 Added 19.49%
1,332,402 $12.7 Million
Q4 2021

Feb 14, 2022
BUY
$15.2 - $35.51 $139,703 - $326,372
9,191 Added 0.83%
1,115,066 $21.2 Million
Q3 2021

Nov 10, 2021
BUY
$21.78 - $40.45 $24.1 Million - $44.7 Million
1,105,875 New
1,105,875 $36.8 Million

Others Institutions Holding TGTX

# of Institutions
340
Shares Held
88.5M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.98B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email